Trevi Therapeutics (TRVI) Tops Q2 EPS by 2c
Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.